Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | LX-101 |
| Synonyms | |
| Therapy Description |
LX-101 comprises an IGF1 variant conjugated to an MTX payload, which inhibits Igf1r signaling and potentially decreases tumor growth (Cancer Res (2026) 86 (7_Supplement): 7873). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| LX-101 | LX101|LX 101 | LX-101 comprises an IGF1 variant conjugated to an MTX payload, which inhibits Igf1r signaling and potentially decreases tumor growth (Cancer Res (2026) 86 (7_Supplement): 7873). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07781891 | Phase II | LX-101 | RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT | Not yet recruiting | USA | 0 |